as mentioned in go
Some Immune-Boosting Cancer Drugs May Pose Rare Heart Risks
Some Immune-Boosting Cancer Drugs May Pose Rare Heart RisksDoctors have found a disturbing downside to some powerful new drugs that harness the immune system to fight cancer.In rare cases, they may cause potentially fatal heart damage, especially when used together.The drugs are called checkpoint inhibitors and they have transformed cancer treatment in recent years by helping the immune system see and attack tumors.However, in less than one percent of patients, the immune system seems to attack not only the tumor but also the heart and other muscles.
in the same way nbcnews
New Cancer Drugs May Damage the Heart
New Cancer Drugs May Damage the Heart
Doctors have found a disturbing downside to some powerful new drugs that harness the immune system to fight cancer: In rare cases, they may cause potentially fatal heart damage, especially when used together."The problem is, no one has this on their radar," so patients are not routinely checked for it, said Dr. Javid Moslehi, head of a Vanderbilt University clinic specializing in heart risks from cancer therapies.Youssef Cohen, 68, undergoes cancer treatment with the drug Keytruda John Moore / Getty Images, fileHe led a team of experts who reported Wednesday in the New England Journal of Medicine about two patients who died of heart trouble two weeks after receiving their first doses of two Bristol-Myers Squibb drugs, Opdivo and Yervoy, for the deadly skin cancer melanoma.Two similar drugs also are on the market, and the study leaders believe they might pose heart risks, too.
additionally nytimes
Lifesaving Cancer Drugs May in Rare Cases Threaten the Heart
Lifesaving Cancer Drugs May in Rare Cases Threaten the Heart
Checkpoint inhibitors have been approved to treat six types of cancer, and are being used for many other types.The drugs are also being combined with one another for added effectiveness.Advertisement Continue reading the main storyThe heart findings should not scare patients away from the drugs, Dr. Moslehi said.He called them "transformative" in cancer treatment and said they offered a "potential for cure."Four checkpoint inhibitors are on the market: ipilimumab (brand name Yervoy), nivolumab (Opdivo), pembrolizumab (Keytruda) and atezolizumab (Tecentriq).
No comments:
Post a Comment